An official website of the United States government
Publication Information
Affiliation
Department II of Internal Medicine and Center for Molecular Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne; Department of Nephrology, University Medical Center Groningen, University of Groningen; Department of Renal Medicine, Aarhus University Hospital; Department of Translational Medical Sciences, Vanvitelli University; University Brest, Inserm; Institute of Physiology, University of Zurich; Department of Genetics, University Medical Center Utrecht; Association PolyKystose France (PKD France); PKD International; Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center Rotterdam; Department Genetics, University Medical Centre Groningen; PKD Familiäre Zystennieren e.V.; PKD Research Group, Laboratory of Pediatrics, Department of Development and Regeneration, KU Leuven; Department of Nephrology, Hemodialysis and Renal Transplantation, CHU and University of Brest; Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboudumc Center of Expertise for Rare Kidney Disorders, Radboud University Medical Center; Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University; Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, Heidelberg University Hospital; Nephrology and Transplantation Department, Necker University Hospital; Department of Nephrology, 1st Faculty of Medicine, General University Hospital; Inherited Kidney Diseases Nephrology Department, Fundació Puigvert Instituto de Investigaciones Biomédicas Sant Pau, Universitat Autònoma de Barcelona; Department of Renal Medicine, University College London; Department of Nephrology, University Medical Center Groningen, University of Groningen
Authors
Müller Roman-Ulrich, Messchendorp A Lianne, Birn Henrik, Capasso Giovambattista, Cornec-Le Gall Emilie, Devuyst Olivier, van Eerde Albertien, Guirchoun Patrick, Harris Tess, Hoorn Ewout J, Knoers Nine V A M, Korst Uwe, Mekahli Djalila, Le Meur Yannick, Nijenhuis Tom, Ong Albert C M, Sayer John A, Schaefer Franz, Servais Aude, Tesar Vladimir, Torra Roser, Walsh Stephen B, Gansevoort Ron T
Studies
Abstract
Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark TEMPO 3:4 trial—marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.